Kim Fox is a UK cardiologist who was paid by Servier, a French drug company, to support clinical trials on ivabradine, a drug for treating angina. The payments were made from 2006 to 2015 to a private company run by Fox and his wife that was involved with contract research. The bulk of the money was taken as profit from the company by Fox and his wife. None of this is illegal. However, it is a remarkable story. The payments amount to a staggering £50m, which shows just how much money is thrown at a new drug. Further, Fox was president of the European Society of Cardiology and chaired its guideline committee that recommended ivabradrine. Ivabadrine has now fallen down the pecking order of drugs of choice for angina. The guideline, in that sense, hasn’t stood the test of time. This is a familiar trajectory. Publication bias talks up the benefits of new drugs early on, with less supportive evidence and information on harms tending …
Kamran Abbasi is the Editor in Chief at The BMJ. He specializes in medicine and healthcare, with a focus on public health, healthcare administration, and the intersection of climate change and health. His work has been featured in notable publications including the Dawn Group of Newspapers, JAMA, and the Bioethics Education Network.